Podcasts about Roche

The Public Service Commissioner says he believes former Police Commissioner Andrew Coster is genuinely sorry, following his resignation as Social Investment Agency Head. Coster's accepted responsibility for shortcomings highlighted in an IPCA report on the handling of complaints against his then Deputy Jevon McSkimming. His final pay will be near $124 thousand. Sir Brian Roche told Mike Hosking Coster's always seemed genuine in all his experiences with him. He says Coster's very sincere and has real courage, and is confident what he says he believes, is true. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Former Police Commissioner Andrew Coster resigned from his position as CEO of the Social Investment Agency following an Independent Police Conduct Authority (IPCA) report into how police handled complaints against former Deputy Commissioner Jevon McSkimming. Public Service Commissioner Sir Brian Roche said the result was 'appropriate', but shared positive experiences working with Coster. Roche told Heather du Plessis-Allan, "I believe him to be a person of integrity and very values-driven." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Ecoutez les infos de ce mardi 02 décembre à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Der "Head of Legal Digital & IT" bei ROCHE berichtet, wie ein Konzern * mit der EU-Digitalregulierung umgeht, * wie er auf Augenhöhe bleibt, * auf was es bei der Implementierung ankommt und * welche Kritik und welche Hoffnung an bezüglich dieser Vorgaben hat. Christian Johner beleuchtet die gleichen Fragestellungen aus der Brille von jemanden, der Einblick in viele andere Unternehmen hat.

Ecoutez les infos de ce mardi 02 décembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mardi 02 décembre à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mardi 02 décembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce mardi 02 décembre à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Hacemos balance en Europa destacando: Airbus, Air France-KLM, TotalEnergies, Roche, RWE y BHP Group. Con Pablo Garcia, director general de Divacons-Alphavalue.

Ecoutez les infos de ce lundi 01 décembre à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 01 décembre à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In dieser Folge spricht Denise mit Dr. David Liesenfeld, Medical Group Lead in der Hämatologie Onkologie bei Roche, über das neue Medizinforschungsgesetz (MFG). Sie beleuchten die geplanten Maßnahmen zur Entbürokratisierung und sprechen darüber, wie Genehmigungsverfahren bei Bundesoberbehörden beschleunigt und die Zusammenarbeit mit Ethikkommissionen harmonisiert werden sollen. Entdecke welche Vorteile die neuen Standardvertragsklauseln bieten und erfahre, wie das Gesetz die Attraktivität für klinische Studien in Deutschland nachhaltig steigern soll! Gibt es Themen, die dich besonders interessieren und zu denen du dir eine zukünftige Episode wünschst? Teile uns deine Ideen und dein Feedback gerne mit.

Ecoutez les infos de ce dimanche 30 novembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 30 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 30 novembre à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

As we think about systems change, it's all too easy to get caught up the technical design of new institutions and 'system architecture'. But if we are being asked to consider a qualitatively different way governing, convening, educating, distributing resources - all of the fundamentals of society -then perhaps we can start by asking: What has LOVE got to do with any of it? As I share at the start of this episode, it's been clear to me that it's difficult to bring the concept of love into such discussions. So I really wanted to explore this a few courageous and amazing individuals, who I knew would be up for it! In this episode you'll hear from four amazing people working in quite different sectors - from existential risk, climate resilience to cognitive science to leadership and communications to teacher training and education. But all united by the willingness to talk about love as central to their work. Dr. Laura Penn is an expert in leadership communication and the speaking arts. As the Founder of The Leadership Speaking School (https://www.theleadershipspeakingschool.com/), she transforms leaders and teams from the world's most well-known companies, business schools and organizations into authentic communicators of the digital age. Her clients include the World Economic Forum, International Olympic Committee, United Nations, World Wildlife Fund for Nature (WWF), IMD Business School, Ebay, Roche, Louis Vuitton Moët Hennessy (LVMH), Nespresso, Salesforce, Logitech, the Union of European Football Associations (UEFA), EHL Hospitality Business School and many more.With her first career as a conservation biologist, Laura is also a distinguished voice in the sustainability sector, empowering her audiences to communicate sustainability with gravitas.https://www.laurapennspeaker.com/linkedin.com/in/laurapennphdJamie Bristow is a writer linking inner and outer transformation, and a policy advisor on the application of inner development and contemplative practices in public life. His work includes influential reports such as Reconnection: Meeting the Climate Crisis Inside Out and The System Within: Addressing the inner dimension of sustainability and systems transformation. Jamie is currently developing his work in a new direction, supported by a two-year fellowship, and is initiating a yet-to-be-announced project with Professor Rebecca Henderson at Harvard University (https://rebeccahenderson.com/). He is a co-founder of the Life Itself Sensemaking Studio; honorary associate of Bangor University; special advisor to the Inner Development Goals; from 2015 to 2023, Jamie played an instrumental role in the UK's All-Party Parliamentary Group on Mindfulness.https://www.linkedin.com/in/jamiebristow/ https://www.jamiebristow.com/Khadija Shahper Bakhtiar is CEO and Founder of Teach For Pakistan - MPP, University of California, Berkeley; BSc Hons., LUMS; Rozan, Islamabad; UN Women, NYC; Fulbright Alum.https://iteachforpakistan.org/ https://www.linkedin.com/in/khadija-shahper-bakhtiar-045b60122/And Andrea Hiott, who you have heard on the podcast previously in episode 209 (https://www.goodimpactlabs.com/podcast/andrea-hiott) is Andrea is a philosopher, cognitive scientist and writer and host of the Love and Philosophy community and channel: https://lovephilosophy.substack.com/

Ecoutez les infos de ce samedi 29 novembre à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 29 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 29 novembre à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 29 novembre à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 28 novembre à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 28 novembre à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 28 novembre à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 28 novembre à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

With Arsenal TOP of BOTH leagues, I ask Art de Roché, Arsenal Writer at The Athetic, are Arsenal the best in Europe?

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelVous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelVous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelVous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Invité : Marc Roche, journaliste et essayiste, auteur du livre "Ma vie chez les Windsor" aux éditions Albin MichelHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Novo Nordisk, leader européen de la pharma en 2023, a vu sa capitalisation chuter de 63 % en deux ans, dépassé par Eli Lilly et son Mounjaro. La concurrence s'intensifie sur le marché des traitements contre l'obésité, avec l'arrivée attendue de nouveaux acteurs comme Roche et Pfizer. Dans « La Story », le podcast d'actualité des « Echos », Pierrick Fay et Myriam Chauvot reviennent sur la bataille de l'obésité dans l'industrie pharmaceutique, bataille arbitrée aussi par Donald Trump.« La Story » est un podcast des « Echos » présenté par Pierrick Fay. Cet épisode a été enregistré en novembre 2025. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste au service industries des « Echos »). Réalisation : Willy Ganne. Musique : Théo Boulenger. Identité graphique : Upian. Photo : Shutterstock. Sons : BFM Business, Loopsider, extrait « La cité de la peur », extrait «L'aile ou la cuisse», Extrait «Taxi 3». Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr/lastory Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Welcome back to Ozempic Weight Loss Unlocked, the show where we break down the latest developments in weight loss medications and what they mean for your health. I'm your host, and today we're diving into some exciting new data and industry shifts that you need to hear about.Let's start with what's happening right now in the weight loss medication world. A recent systematic review of over forty thousand adults found that semaglutide and tirzepatide significantly outperform older medications in achieving meaningful weight loss. In clinical trials, semaglutide resulted in a fourteen point nine percent reduction in body weight over sixty eight weeks, while tirzepatide led to a twenty point nine percent reduction. That's substantial progress compared to earlier options like liraglutide, which delivered only four to five percent weight loss.But here's something important our listeners need to understand: clinical trial results don't always match real world outcomes. When researchers looked at actual users after one year, those taking semaglutide lost seven point seven percent of their body weight, and those on tirzepatide lost twelve point four percent. Why the difference? About fifty percent of patients discontinued treatment during that first year, and eighty percent took lower dosages than prescribed.Speaking of usage, the numbers are staggering. Approximately one in eight American adults, or around twelve percent, have used a glucagon like peptide one medication at some point. Among people diagnosed with diabetes, that number jumps to forty three percent. The average age of users in the United Kingdom is forty four years old, with people aged forty to fifty nine making up more than half of all users.Now let's talk money, because cost remains a major barrier. The monthly out of pocket cost for Ozempic in the United States can reach as high as twelve hundred dollars for uninsured individuals. This pricing has created a competitive marketplace. In November twenty twenty five, Pfizer won a bidding war with Novo Nordisk to acquire obesity drug developer Metsera, giving them injectable and oral glucagon like peptide one candidates expected to enter clinical trials soon.But there's even more competition coming. Research indicates that several pharmaceutical companies including AstraZeneca, Zealand Pharma, Roche, and Amgen are expected to enter the glucagon like peptide one market with multiple drug launches planned between twenty twenty seven and twenty thirty two.Interestingly, a new alternative is emerging. A medication called eloralintide, which targets a different hormone called amylin instead of glucagon like peptide one, showed promising results. In a phase two clinical trial with two hundred sixty three participants, those receiving eloralintide experienced average weight loss between nine and twenty percent after forty eight weeks, compared to only zero point four percent in the placebo group. Up to ninety percent of participants on eloralintide improved by at least one body mass index category, and the study showed improvements in cardiometabolic risk factors including waist circumference, blood pressure, and blood sugar management.Our listeners should know that not everyone responds equally to these medications. Past studies show that as much as seventeen percent of glucagon like peptide one users may be non responders to the medication. This is why having multiple treatment options with different mechanisms of action matters so much.One final note worth mentioning: the rise in glucagon like peptide one use has sparked increased demand for cosmetic surgeries to remove loose skin following significant weight loss. Procedures like arm lifts, thigh lifts, and tummy tucks have all seen increased demand.Thank you so much for tuning in to Ozempic Weight Loss Unlocked. Please make sure to subscribe so you don't miss our next episode covering even more developments in this rapidly evolving space. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Hosted by Ernie Whitman. To start things off, Benny Carter plays a swinging tune. Betty Roche sings, Trouble Why Can't You Let Me Be. The King Cole Trio plays and…

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

The pain point is real: you want to be authentic and build genuine audience connection, but you worry about oversharing from a place of raw emotion or current struggle. For hosts focused on mental health and transformation, the line between helpful vulnerability and emotional burnout is thin. In this episode of Podcasting Unlocked, we sit down with Lauren Roche to explore the powerful strategy of sharing from a healed place—not from the "wound." Discover how to use your show to take listeners on an honest healing journey, set healthy sharing boundaries, and align your vulnerability with your purpose for genuine podcast growth. This week, episode 245 of Podcasting Unlocked is about the power of sharing your personal story from a healed place! Lauren Roche, a UMD Smith School of Business graduate, is a young DC professional focused on community and open conversation. She worked in consulting at Deloitte for 5.5 years, specializing in tech projects like product management and design. She left to dedicate herself to her wellness brand, The Naked Truth with Lauren. This brand aims to revolutionize mental health, mindfulness, and manifestation through a podcast, social media, workshops, coaching, and gratitude, building a supportive community that helps busy professionals combat loneliness and prioritize well-being.In this episode of Podcasting Unlocked, I'm Lauren Roche sharing the importance of not oversharing experiences you are not healed from yet and actionable steps you can take right now to embrace your vulnerability in your podcast. Lauren and I also chat about the following: Share from the Healed Place: For maximum impact and sustained audience connection, always share your personal story from a place of healing and resolution, not from the active, raw emotional "wound."Strategic Vulnerability: Learn how to determine sharing boundaries—how much is too much—to protect your own mental wellness while still being authentically present for your audience.Guide the Healing Journey: Use your show to invite listeners to come along on your journey of transformation, making your struggles relatable and your solutions aspirational.Find Your Community: Discover the value of connecting with aligned content creators in strategic groups like the Feminist Podcasters Collective for support and genuine podcast growth.Your vulnerability is a powerful tool for connection, but it must be used with intention. This week, reflect on the last personal story you shared on your podcast: Did you share from the healed place?Be sure to tune in to all the episodes to receive tons of practical tips on turning your podcast listeners into leads and to hear even more about the points outlined above. Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me! And don't forget to follow, rate and review the podcast and tell me your key takeaways!Learn more about Podcasting Unlocked at https://galatimedia.com/podcasting-unlocked/ CONNECT WITH LAUREN ROCHE:WebsiteInstagramPodcastCONNECT WITH ALESIA GALATI:InstagramLinkedInWork with Galati Media! Work with Alesia 1:1Proud member of the Feminist Podcasters Collective.

Sandra Walker is CEO, Viacern Group, and Venture Partner at Hard Climate, a seasoned and inspirational pharma and biotech executive leading Commercial, Medical Operations and Excellence, Government Affairs, Global Strategy and Product Planning at companies such as Genentech, Roche, Eli Lilly and Abbvie. She delivered a state-of-the-art, candid, and intriguing keynote presentation that forces you to reflect on the language and process you use to make decisions in medicine, healthcare, and how you can challenge your current approaches and biases using neuroscience-based practical, real-world solutions to make bolder decisions with evidence to drive innovation forward.3:10 Speaker Introduction4:12 Turning Innovation into OutcomesThree Common recurring Decision PatternsExplaining Biases in Decision-makingPractical Solutions to Transform DecisionsThe Bolder WayDecision Audit5:56 Three Invisible Decision Patterns6:37 Status Quo Bias8:51 Countermoves You Can Use vs Status Quo Bias9:29 Confirmation Bias11:54 10-Minute Challenge Round To use Vs. Confirmation Bias 13:09 Completion Bias - Relief of Feeling Done16:30 Explaining the Brain under Pressure with Neuroscience 18:50 How to Quiet the Noise in BiasLabel the state – identify the bias, problem, riskExternalize thinking – move ideas onto paper to createpublic reasoningTeach the cheerleader to celebrate learning not justfinishing.Train for Learning not Finishing21:01 The Bolder Way - 6 steps to turn Awareness into ActionB - Bias and Blind Spots visualization (see the invisible)O - Observe: Disciplined CuriosityL - Learn: Broadened PerspectivesD - Decide with clarity and transparencyE - Empower: Trust with ContextR - Recalibrate: Boldness into Learning27:11 Bolder Way Framework Aligned to the Scientific Method 28:02 Language You Use is Key to Decision Outcome28:38 The Decision Audit to Deliver Clarity in 5 Minutes31:09 How Speed of Decision Impacts the Outcome

About the Guest(s):Maddy Roche - Maddy handles all marketing, growth, and prospect engagement for Childfree Trust® - the first nationwide medical and financial POA, executor and trustee representation service for the Childfree population. She understands the challenges of being Childfree as it relates to estate planning and is passionate about educating her community about ways to prepare.Before joining Childfree Trust®, she was XYPN's first employee and host of XYPN's podcast Behind the Advisor. In her previous roles as Vice President and Executive Business Coach, she helped build and lead the departments that deepen XYPN's membership value.Maddy has seen, heard, and helped thousands of financial planners throughout their entrepreneurial journeys with energy, expertise, and compassion.Episode Summary:In this enlightening episode of Money Roots, host Amy Irvine is joined by Maddy Roche, Chief Growth Officer at Child Free Trust, for an in-depth discussion on a timely financial planning topic: estate planning for child-free individuals. Maddy's expertise comes to the forefront as they explore the common misconceptions surrounding estate planning for those without children, emphasizing the need for a structured plan to safeguard one's legacy. This conversation is critical for the 25% of Americans who lack children, whether by choice or circumstance.The conversation delves into the innovative solutions offered by Child Free Trust, a groundbreaking initiative poised to fill the "fiduciary void" faced by child-free adults. By January, the organization will officially provide nationwide services as medical power of attorney, financial power of attorney, executor, and trustee, uniquely catering to the 15 million Americans over 55 without children. Amy and Maddy discuss the substantial need for such services and how the digital platform will facilitate critical information sharing across all 50 states, ensuring individuals have someone to rely on in times of medical emergencies, cognitive decline, or death. This episode shines a light on the future of estate planning, presenting options for those who previously had limited solutions.Key Takeaways:Child Free Trust offers the first nationwide estate planning service tailored for individuals without children.Estate planning isn't just about preparing for death; it's also about emergency preparedness for medical situations and cognitive decline.The service covers all 50 states, providing comprehensive solutions that include medical and financial power of attorney, executor, and trustee roles.Many child-free individuals face the "fiduciary void," lacking a designated representative to act on their behalf amid emergencies.Maddy emphasizes the importance of removing emotional biases in decision-making, opting for professional, impartial third-party services.Notable Quotes:"A lot of people say, oh, it must be so easy to plan for estate planning purposes when you don't have kids. I'm like, yeah, like, who do you leave your stuff to? It's actually a big problem." – Amy Irvine"There are 25% of Americans that don't have kids either by choice or by circumstance." – Maddy Roche"15 million Americans over 55 don't have children. It's a huge market; it's a huge underserved market in so many ways." – Maddy Roche"We really try to neutralize some of this ahead of time, and working with a planner like you can help." – Maddy Roche"This takes that out and there's continuity, so it doesn't matter if there's any health events, there's that continuity of care that continues." – Amy IrvineResources:Child Free Trust – Offering estate planning services tailored for child-free individuals.

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos Rheinmetall hat Ziele. AkzoNobel & Axalta fusionieren. Klarna-Aktie fällt trotz vieler Nutzer. Roche hat Studie. China-Riesen Baidu und PDD Holdings schwächeln. Home Depot vermisst Stürme. RTL senkt Prognose. Xiaomi boomt mit E-Autos. Cloudflare ist down. Hinter KFC, Taco Bell und Pizza Hut steht eine Firma: Yum! Brands (WKN: 909190). Und die überlegt jetzt die schwächste Kette (Pizza Hut) abzuspalten. Apple hat 750 Mio. $ für die F1-Rechte in den USA gezahlt. Währenddessen hat Formel-1-Mutter Liberty Media (WKN: A3ERLT) MotoGP übernommen. Macht das Sinn? Diesen Podcast vom 19.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine factory in Saratoga Springs, New York, into a state-of-the-art drug manufacturing plant. This investment reflects a broader industry trend towards enhancing domestic manufacturing capabilities to ensure supply chain resilience. Similarly, CSL is channeling $1.5 billion into U.S. plasma-based manufacturing over the next five years. These investments are critical as plasma-derived therapies continue to play a vital role in treating various conditions, necessitating robust manufacturing infrastructure to meet growing demand.In clinical research, Merck's Winrevair has shown promising results in a proof-of-concept study for heart failure patients. This advancement highlights ongoing efforts to address one of the leading causes of morbidity and mortality worldwide—heart failure. The study paves the way for further exploration of activin signaling inhibitors in cardiovascular therapies.On the regulatory front, Eli Lilly has expanded its market reach with the approval of its Alzheimer's medication for distribution in India. This milestone represents progress in tackling the global Alzheimer's disease burden, an ailment that presents significant challenges to healthcare systems worldwide.The FDA's recent critique of AstraZeneca's Farxiga advertisement underscores the importance of accuracy in pharmaceutical marketing. The agency's concerns about potential misleading impressions emphasize ongoing regulatory vigilance to align marketing practices with approved therapeutic uses and ensure patient safety.Shifting to business strategies, Zymeworks' transition towards becoming a 'royalty-driven organization' marks an evolution in biotech business models. By leveraging successful licensing frameworks, Zymeworks aims to enhance revenue streams while focusing on innovation without the traditional constraints of direct commercialization.In cardiovascular therapeutics, Cytokinetics is positioning itself strategically by funding a heart registry, signaling an intensifying competitive landscape as companies vie for leadership in this critical area of healthcare.Roche's development of giredestrant, an oral selective estrogen receptor degrader (SERD), has achieved success in a phase 3 adjuvant breast cancer trial. This positions Roche to capture an unoccupied niche within the competitive breast cancer treatment market and highlights a trend towards targeted therapies with potentially significant patient outcomes.Addressing side effects associated with GLP-1 receptor agonists, Vanda Pharmaceuticals is making strides with tradipitant to mitigate nausea and vomiting induced by Wegovy. As GLP-1 agonists gain traction for their metabolic benefits, adjunct therapies addressing side effects are becoming increasingly pertinent.In digital health initiatives, Humana's collaboration with Epic aims to automate insurance verification and patient check-ins, aligning with federal interoperability goals. This represents a broader industry shift towards digital solutions designed to streamline administrative processes and enhance patient experience.Meanwhile, Lonza's expansion at its Stein facility in Switzerland underscores ongoing capacity-building efforts among contract development and manufacturing organizations (CDMOs). Such expansions are crucial as they provide biopharmaceutical companies with the neSupport the show

Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job.  This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job.  You have online opportunities tomorrow! Participate in the National MS Society's Hispanic LatinX MS Experience Summit, or catch the International Progressive MS Alliance's global webcast, How Existing Drugs Could Transform MS Treatment. We have all the info for you to register for either or both!   If you purchase your health insurance through the ACA Healthcare Marketplace, you've probably already been notified that your premiums will skyrocket in 2026. MS Activist, Sarah Quezada, shares how those premium increases will affect her family. Roche has announced the outcomes of Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS. It's positive news, and we have the details! Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  University of Illinois researchers say yes! We're sharing the details. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: It's National Family Caregiver Month  :22 The MS Care Partner Connection  :34 The National MS Society is hosting the Hispanic LatinX MS Experience Summit TOMORROW!  2:20 The International Progressive MS Alliance Global Webcast is TOMORROW!  2:51 Sarah Quezada shares how astronomical increases in ACA health insurance premiums will affect her family  3:46 Roche announces outcomes for Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS  11:59 Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  13:43 Diana Grazio discusses how she manages her role as a caregiver while holding down a full-time job  16:07 Share this episode  29:10 Next week's episode  29:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/429 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Online Survey https://s.alchemer.com/s3/Perspectives-on-MS SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy REGISTER: The Hispanic LatinX MS Experience Summit https://nationalmssociety.org/resources/get-support/education-programs-and-library/hispanic-latinx-ms-experience REGISTER: International Progressive MS Alliance Global Webcast https://msif.org/news/2025/11/03/alliance-webcast VISIT: The MS Care Partner Connection https://mscarepartnerconnection.com STUDY: Nanoparticle-Boosted Myeloid-Derived Suppressor Cell Therapy for Immune Reprogramming in Multiple Sclerosis https://www.science.org/doi/10.1126/sciadv.ady4135 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 429 Guests: Sarah Quezada, Diana Grazio Privacy Policy

Membership | Donations | Spotify | YouTube | Apple Podcasts | Discord | FB GroupThis week (actually, April) I speak with Rimma Boshernitsan (Website | LinkedIn), a speaker, interviewer, facilitator, and advisor who has partnered with senior leadership at Fortune 500 companies—including Google, Kaiser Permanente, Roche, TATA, and Aesop—guiding them through transformation and growth. Her writing has appeared in Fast Company, Inc. Magazine, Tech Crunch and Forbes.She began her career in management consulting at Deloitte, focusing on M&A and large-scale transformation, before moving into industry advising across healthcare, consumer business, and telecommunications. Later work in the art world taught her how cultural and political insights could drive innovation and transformation in business, leading her to found DIALOGUE in 2016.She now combines strategic foresight, human-centered innovation, and interdisciplinary thinking to help her clients reframe challenges, identify opportunities, and lead with intention. She sits on the board of trustees at Headlands Center for the Arts and on the SECA Council Board at SFMOMA, and is also an advisor to Stanford's Women in Design Program.Her most recent focus is in co-intelligence: integrating human, machine, and planetary intelligence to build future-facing organizations.I'm glad to have such an excellent partner in conversation to, as the Taoists say, “Feel our way across the river stone by stone” in a discussion about all of this and more: the re-emergence of nomadic populations and intentional communities, fumbling toward an idea of planetary culture, the role of intuition in leadership and biophilia in the design of our work spaces...it's a marvelously nondisciplinary co-exploration.There are well over a dozen episodes in the editing queue and founding members can access the entire trove of unedited conversations before they're released:✨ Show Links• Dig into nine years of mind-expanding conversations• Learn more about the Humans On The Loop project and its goals• Browse the books we discuss on the show at Bookshop.org• Contact me if you have a problem you think I can help you solve• Explore the interactive knowledge graph grown from over 250 episodes• Explore the Google Notebook for How To Live In The Future, my five-week science and philosophy course at Weirdosphere✨ Mentioned Media & PeopleIn Threads' dwindling engagement, social media's flawed hypothesis is laid bareIn a Time of Stress, Neuroaesthetic Spaces and Places Create a Path to Healing and HopeThe Triad of Intelligences: Harnessing Machine, Planetary, and Human Intuition in The Age of AIDIALOGUE Interviews: Ivy RossDIALOGUE Interviews: Susan MagsamenDIALOGUE Interviews: Kevin KellyMore Is Different: Broken symmetry and the nature of the hierarchical structure of scienceNikki SilvaBruce LiptonEd BernaysKen Wilber This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit michaelgarfield.substack.com/subscribe